Aldeyra Therapeutics, Inc. (ALDX)
Market Cap | 120.39M |
Revenue (ttm) | n/a |
Net Income (ttm) | -55.85M |
Shares Out | 59.90M |
EPS (ttm) | -0.94 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,248,484 |
Open | 2.100 |
Previous Close | 2.100 |
Day's Range | 1.905 - 2.100 |
52-Week Range | 1.140 - 7.200 |
Beta | 0.90 |
Analysts | Strong Buy |
Price Target | 9.50 (+372.64%) |
Earnings Date | May 20, 2025 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 372.64% from the latest price.
News

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of ...

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it...

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations ...

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce t...

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations ...

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law
NEW YORK, May 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of ...

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of ...

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violatio...

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential vio...

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , April 29, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aldeyra Therapeutic...

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TechTarget, Inc. (NASDAQ:TTGT) ...

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money
NEW YORK CITY, NY / ACCESS Newswire / April 28, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential vio...

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations o...

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violatio...

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations o...

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential vio...

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violatio...

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations o...

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential vio...

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data....

ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX)
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations o...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Com...

Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Com...

ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. Investors are Reminded of the Ongoing Securities Investigation – Contact BFA Law (NASDAQ:ALDX)
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations o...